The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

  1. Hurchla, M.A.
  2. Garcia-Gomez, A.
  3. Hornick, M.C.
  4. Ocio, E.M.
  5. Li, A.
  6. Blanco, J.F.
  7. Collins, L.
  8. Kirk, C.J.
  9. Piwnica-Worms, D.
  10. Vij, R.
  11. Tomasson, M.H.
  12. Pandiella, A.
  13. San Miguel, J.F.
  14. Garayoa, M.
  15. Weilbaecher, K.N.
Aldizkaria:
Leukemia

ISSN: 0887-6924,  1476-5551

Argitalpen urtea: 2013

Alea: 27

Zenbakia: 2

Orrialdeak: 430-440

Mota: Artikulua

DOI: 10.1038/LEU.2012.183 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus